The AAN Therapeutics and Technology Assessment subcommittee has published its report on the safety and efficacy of mitoxantrone in multiple sclerosis, concluding that the risks of systolic dysfunction and therapy-related leukemia are higher than previously estimated (Marriott et al. Neurology 2010; 74: 1463-1470; free full text at www.neurology.org/cgi/reprint/74/18/1463).